INS and metabolic syndrome: RCI-1502 may alleviate dyslipidemia by stimulating phosphorylation and adenosin monophosphate kinase activation, exerting direct effects on vascular endothelium, decreasing the inflammatory response, and improving insulin sensitivity and glucose tolerance 83.